Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease

American Journal of Cardiology

Volumn 91, Issue 5, 2003, Pages 575-580

  Sprecher, Dennis L ^a   Watkins, Timothy R ^b   Behar, Solomon ^b   Brown, W Virgil ^b   Rubins, Hanna B ^b   Schaefer, Ernst J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANGIOGRAPHY; BLOOD VESSEL DIAMETER; CLINICAL TRIAL; EDITORIAL; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK;

EID: 0037374186     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03309-X     Document Type: Editorial

References (59)

1. Gordon D.J., Knoke J., Probstfield J.L., Superko R., Tyroler H.A. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men the Lipid Research Clinics Coronary Primary Prevention Trial . Circulation. 74:1986;1217-1225.
2. Sprecher D.L. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol. 82:1998;49U-56U.
3. Kannel W.B. High-density lipoproteins epidemiologic profile and risks of coronary artery disease . Am J Cardiol. 52:1983;9B-12B.
4. Assmann G., Cullen P., Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 19(suppl A):1998;A2-A11.
5. Goldbourt U., Medalie J.H. High density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study. Am J Epidemiol. 109:1979;296-308.
6. Foody JM, Ferdinand FD, Pearce GL, Lythe BW, Cosgrove DM, Sprecher DL. HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery, 20-year experience from The Cleveland Clinic Foundation. Circulation 2000;102:III-90-III-94.
7. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 256:1986;2835-2838.
8. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease . N Engl J Med. 317:1987;1237-1245.
9. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol. 17:1997;1114-1120.
10. Miller M., Seidler A., Moalemi A., Pearson T.A. Normal triglyceride levels and coronary artery disease events the Baltimore Coronary Observational Long-Term Study . J Am Coll Cardiol. 31:1998;1252-1257.
11. Assmann G., Schulte H. Role of triglycerides in coronary artery disease lessons from the Prospective Cardiovascular Munster Study . Am J Cardiol. 70:1992;10H-13H.
12. Castelli W.P. Epidemiology of triglycerides a view from Framingham . Am J Cardiol. 70:1992;3H-9H.
13. Burchfiel C.M., Laws A., Benfante R., Goldberg R.J., Hwang L.J., Chiu D., Rodriguez B.L., Curb J.D., Sharp D.S. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation. 92:1995;1430-1436.
14. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease an eight-year follow-up in the Copenhagen Male Study . Circulation. 97:1998;1029-1036.
15. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
16. Carlson L., Oro L. The effect of nicotinic acid on plasma free fatty acids. Demonstration of a metabolic type of synpathicolysis. Acta Med Scand. 172:1962;641-645.
17. Carlson L. Studies on the effect of nicotinic acid on catecholamide stimulated lipolysis in adipose tissue in vitro. Acta Med Scand. 173:1963;719-722.
18. Brown M., Goldstein J. Drugs used in the treatment of hyperlipoproteinemias. Gilman AG, Goodman L., Rall T., Murad F. The Pharmacological Basis of Therapeutics. 1985;827-845 Macmillan, New York.
19. Luria M.H. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med. 148:1988;2493-2495.
20. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 17:1997;2020-2028.
21. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
22. Heller F., Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol. 25:1983;57-63.
23. Malmendier C.L., Lontie J.F., Delcroix C., Dubois D.Y., Magot T., De Roy L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 77:1989;139-149.
24. Breyer E.D., Le N.A., Li X., Martinson D., Brown W.V. Apolipoprotein C-III displacement of apolipoprotein E from VLDL effect of particle size . J Lipid Res. 40:1999;1875-1882.
25. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem. 272:1997;27307-27312.
26. Lamb R.G., Koch J.C., Bush S.R. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion. Biochim Biophys Acta. 1165:1993;299-305.
27. Mann C.J., Yen F.T., Grant A.M., Bihain B.E. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 88:1991;2059-2066.
28. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 96:1995;741-750.
29. Schaefer E.J., Lamon-Fava S., Cole T., Sprecher D.L., Cilla D.D. Jr, Balagtas C.C., Rowan J.P., Black D.M. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Atherosclerosis. 127:1996;113-122.
30. Davignon J., Montigny M., Dufour R. HMG-CoA reductase inhibitors a look back and a look ahead . Can J Cardiol. 8:1992;843-864.
31. Schoonjans K., Peinado-Onsurbe J., Fruchart J.C., Tailleux A., Fievet C., Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 452:1999;160-164.
32. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853.
33. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., Taskinen M.R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 96:1997;2137-2143.
34. Effect of fenofibrate on progession of coronary-artery disease in type 2 diabetes the Diabetes Atherosclerosis Intervention Study a, randomised study . Lancet. 357:2001;905-910.
35. Heinonen O.P., Huttunen J.K., Manninen V., Manttari M., Koskinen P., Tenkanen L., Frick M.H. The Helsinki Heart Study coronary heart disease incidence during an extended follow-up . J Intern Med. 235:1994;41-49.
36. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 341:1999;410-418.
37. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., Rubins H.B. Relation of gemfibrozil treatment and lipid levels with major coronary events a randomized controlled trial . JAMA. 285:2001;1585-1591.
38. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer ES, Faas FH, Anderson JW, for the VA-HIT Study Group. Diabetes, plasma insulin, and cardiovascular disease. Arch Intern Med 2002;162:2597-2604.
39. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention study. Circulation 2000;102:21-27.
40. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418.
41. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381.
42. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients long-term benefit with niacin . J Am Coll Cardiol. 8:1986;1245-1255.
43. Brown B., Xue-Qiao Z., Chait A., Fisher L., Cheung M., Morse J., Dowdy A., Marino E., Bolson E., Alaupovic P., Frohlich J., Albers J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592.
44. Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W.J., Cashin-Hemphill L., Hodis H.N., De Boer L.W., Mahrer P.R., Masteller M.J., Vailas L.I., et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med. 119:1993;969-976.
45. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240.
46. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyorala K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
47. Sacks F.M., Moye L.A., Davis B.R., Cole T.G., Rouleau J.L., Nash D.T., Pfeffer M.A., Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol And Recurrent Events trial. Circulation. 97:1998;1446-1452.
48. Gotto A.M. Jr, Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.Y., Langendorfer A., Beere P.A., Watson D.J., Downs J.R., de Cani J.S. !Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (A.F.C.A.P.S./TexCAPS). Circulation. 101:2000;477-484.
49. Hunninghake D., Knatterud G., Campeau L., White C., Domanski M., Forrester J., Gobel F., Geller N., Herd J., Hoogwerf B., Rosenberg Y. Baseline HDL-cholesterol and triglycerides as predictors of progression of atherosclerosis in saphenous vein grafts (abstr). NHLBI Post-CABG clinical trial. Circulation. 96:1997;I-413.
50. Syvanne M., Nieminen M.S., Frick M.H., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., Ehnholm C., Taskinen M.R. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation. 98:1998;1993-1999.
51. Johansson J., Olsson A.G., Bergstrand L., Elinder L.S., Nilsson S., Erikson U., Molgaard J., Holme I., Walldius G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscler Thromb Vasc Biol. 15:1995;1049-1056.
52. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
53. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 20:2000;2106-2112.
54. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., Johansson J., Karpe F., Cercek B. Effects of recombinant apolipoprotein A-I (Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 97:1998;780-785.
55. Claudel T., Leibowitz M.D., Fievet C., Tailleux A., Wagner B., Repa J.J., Torpier G., Lobaccaro J.M., Paterniti J.R., Mangelsdorf D.J., Heyman R.A., Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA. 98:2001;2610-2615.
56. Oliver W.R. Jr, Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA. 98:2001;5306-5311.
57. Pearson T., Rapaport E., Criqui M., Furberg C., Fuster V., Hiratzka L., Little W., Ockene I., Williams G. Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association writing group. Circulation. 90:1994;3125-3133.
58. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention . Atherosclerosis. 140:1998;199-270.
59. JAMA. 285:2001;2486-2497.